Cargando…
Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare.
Mitomycin, ifosfamide and cis-platin are three of the most active single agents in the chemotherapy of non-small cell lung cancer. We have combined them for a phase 2 study in patients with inoperable non-small cell lung cancer. The regimen ('MIC') comprised: mitomycin 6 mg m-2, ifosfamide...
Autores principales: | Cullen, M. H., Joshi, R., Chetiyawardana, A. D., Woodroffe, C. M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1988
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246601/ https://www.ncbi.nlm.nih.gov/pubmed/2846024 |
Ejemplares similares
-
Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer.
por: Giaccone, G., et al.
Publicado: (1987) -
MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines
por: Kumar, Smriti, et al.
Publicado: (2011) -
Dendrimers Bind Antioxidant Polyphenols and cisPlatin Drug
por: Abderrezak, Amine, et al.
Publicado: (2012) -
Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture.
por: Kohno, N., et al.
Publicado: (1988) -
On the Mechanism of Action of the Antitumor Drug cis-Platin
(cis-DDP) and its Second Generation Derivatives
por: Aletras, Vasilis, et al.
Publicado: (1995)